Pricing is intensifying public debate and regulatory scrutiny surrounding these medications. Notably, in January 2025, Novo Nordisk's semaglutide-based GLP-1 drugs (including Ozempic and Wegovy) were listed among the drugs subject to Medicare pricing negotiations (as part of the Inflation Reduction Act) set to take effect in 2027.